Applications

1632 – PSMA PET/CT imaging for informing treatment of patients with prostate cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) and Computed Tomography (CT) imaging involves the administration of one of several radiopharmaceuticals that share the characteristic of highly specific binding to PSMA. PSMA is present in much higher concentrations in prostate cancer cells than in normal prostate and other tissues. This overexpression of PSMA by prostate cancers allows for highly specific detection of tumour sites throughout the body. The advantages of PSMA PET/CT are particularly apparent for men in whom spread has occurred outside the prostate gland both at staging and later in the course of the disease and for whom prognosis is significantly impaired.

Type: Investigative

Medical condition this application addresses

Prostate cancer is the most commonly diagnosed cancer (>19,000 cases pa) and second most common cause of cancer death (>3,000 pa) in Australian men.Between 1986–1990 and 2011–2015, five-year relative survival from prostate cancer improved from 59% to 95%. More than 90,000 Australians are estimated to be living with prostate cancer.

Meetings to consider this application

  • PASC meeting: 13 August 2020
  • ESC meeting: 10 to 11 June 2021
  • MSAC meeting: 29 to 30 July 2021